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Conversely, there is minimal data on the impact of the TCR-repertoire on survival after conventional (i.e. non-checkpoint targeting) multi-agent therapy in solid-tumors or lymphomas. In DLBCL the relationship between the intratumoral TCR-repertoire and the TME and the prognostic impact of the TCRrepertoire after R-CHOP remains unclear.
However detailed analyses of the TCR-repertoire have however been performed in the context of chronic viral infections. Here, a diverse repertoire of T-cells has long been thought to be critical for effective host resistance to persistent infections. (8) (9) (10) (11) (12) In longitudinal studies in patients with asymptomatic human immunodeficiency virus (HIV), a dynamic bi-directional adaptive interplay between viral epitope escape mutants and the T-cell clonal repertoire has been demonstrated. (8) In this scenario, a large HIV-specific T-cell clone was functionally equivalent to numerous modest sized HIV-specific T-cell clones in preventing disease progression. However, over reliance on a single dominant Tcell clone permits the emergence of virus immune escape mutants that predispose to disease progression. (13) (14) (15) There may be parallels between these processes and those active in lymphoma, however the importance of repertoire diversity in controlling human B-cell lymphomas and its impact on survival remains unproven.
The diversity of T-cells is determined by their TCR. The complimentary determining region 3 (CDR3) of the TCRβ chain is the most variable portion of the TCR and is critical for MHC-peptide complex recognition. (16, 17) The range of individual TCR-bearing T-cell clones that comprises the repertoire specific for a particular antigenic MHC-peptide complex varies substantially in terms of TCR frequency and diversity. A consequence of this specificity is that the TCRβ CDR3 sequence can be used as a 'molecular tag' to identify each T-cell clone.
In this study we applied high-throughput sequencing of the CDR3 region of TCRβ to comprehensively interrogate DLBCL nodal tissues. Data was collated with gene expression and survival to clarify the relationship between the clonal complexity of intra-tumoral T-cells, the TME and outcome after conventional front-line R-CHOP therapy.
Research. 
Materials and Methods

Study Populations
The study was approved by Ethics Committees at participating sites. The cohort comprised 92 adult patients with histologically confirmed DLBCL (and sufficient DNA quantity of at least 500ng) collected from two centres (Princess Alexandra Hospital, Brisbane and Canberra Hospital). The median follow-up was 3.6 years (range 0.02-8.9 years). All patients received R-CHOP, and were otherwise selected solely on the basis of FFPE tissue and clinical annotation (including survival data) availability. Only de novo cases of DLBCL were included. Grade IIIB or transformed follicular lymphoma, HIV-positive and post-transplant patients were excluded. Twelve non-diseased, normal lymph node tissues (purchased from ProteoGenex Inc. CA) obtained from individuals without lymphoma were also analysed. Twenty four tumor samples from patients with melanoma from a publically available cohort, that were treated with anti-PD1 immune checkpoint therapy were used to compare results obtained from the lymphoma biopsies. (7) High-throughput sequencing For FFPE samples, DNA was extracted using RecoverAll total nucleic acid extraction kit for FFPE (Ambion, Life Technologies, Carlsbad, CA, USA) as per manufacturer's instructions. TCRβ CDR3 regions were amplified from between 500ng-2μg of DNA. All samples had the immuno-SEQ™ assay performed at Adaptive Biotechnologies (Seattle, WA, USA). Briefly, this involved a multiplex 
Assessment of the TCR-repertoire
The 'total productive sequences' were first calculated. This value is dependent on how many cells carry a particular TCR rearrangement and how many copies a small T-cell population. Four samples were excluded using this cut-off. Then, the percentage of total T-cells ('% total T-cells') as a proportion of all cells within the biopsy was determined using the following calculation: productive TCRs/(Input genomic DNA (ng)*156 diploid genomes/ng DNA).
The numbers of individual productive T-cell clones in the samples were then identified by calculating the number of 'productive uniques'. This is a measure of the number of functional T-cells with a distinct TCR rearrangement (an estimate of how many clones exist in the entire repertoire), and is also termed "richness". 
Statistical analysis
Values between groups of data were tested for statistical significance using the 2-tailed non-paired Mann-Whitney test. Categorical data were compared using 
Results
The immuno-SEQ Assay correlates with other methods of T-cell detection
For stringency, so as to exclude clonality measures being potentially influenced by a small T-cell population, only samples with sufficient number of productive TCRs present were included in the analysis (arbitrarily chosen as at least 100 normalised productive TCRs). Of the 92 initial patient samples, 88 had sufficient levels of productive TCRs to be included for further analysis. Median age was 62 years (range 27.5-85.8 years), 63% were male, and the international prognostic 
DLBCL nodes have a narrower TCR-repertoire than non-diseased nodes
The TCR-repertoire in the DLBCL biopsies and 12 non-diseased normal lymph nodes was compared, outlined in Table 1 . The amount of input DNA and number of total input cells was almost identical between the groups. However, the % total T-cells were ~7-fold higher in the non-diseased normal lymph nodes compared to DLBCL biopsies (p<0.0001). There was a marked increase in clonality, and consistent with this, reduced diversity (entropy) in DLBCL biopsies relative to non-diseased normal lymph nodes (both p<0.0001). There was also an increased % maximal frequency clone within DLBCL biopsies relative to nondiseased normal lymph nodes (p<0.0001). These findings are consistent with an abnormally narrow TCR spectrum of T-cells within tumor samples. The distribution of the % top 100 maximal frequency clones is illustrated in Figure 1 .
Within patient biopsies, higher diversity (entropy) was present in those in whom the % maximal frequency clone was below the median level (p<0.001). Only within particular T-cell groupings. However, the ratio of CD4/CD8 mRNA measured by Nanostring™ grouped according to level of the % maximal frequency clone, with higher CD8 levels relative to CD4 associated with greater T-cell clonal expansions (Figure 2) .
A narrow TCR-repertoire associates with adverse outcome
We next investigated the impact of the TCR-repertoire on outcome following R-CHOP. To address whether biopsy tissues from patients with particularly skewed (i.e. highly dominant) clonal expansions were associated with outcome, we tested the impact of % maximal frequency clone on survival. This cut-off was established using the upper 95% confidence interval for the mean value of the dominant clones of all samples. These highly dominant i.e. a markedly expanded clones were termed 'high % maximal frequency' clones. These were present in 17% of cases, with the remaining 83% classified as having 'low % maximal frequency' clones. Interestingly, the presence of a high % maximal frequency in the tumor biopsy in the whole cohort was associated with an inferior 4-year OS of 60.0% (95% C.I. 31.7-79.6%), compared to 79.8% (95% C.I. 66.7-88.5%, p=0.005) in patients with a non-dominant or 'low % maximal frequency' clone 
Comparison of the TCR repertoire between melanoma and DLBCL
We compared our results from patients with DLBCL treated with front-line multi-agent therapy, to a publicly available cohort of patients with melanoma treated with anti-PD1 therapy.(7) In this cohort, melanoma patients responsive to anti-PD1 therapy had significantly higher levels of clonality and a trend for a higher maximal frequency clones compared to non-responders.(7) Intriguingly, we observed that the TCR environment was different between lymphoma and melanoma. The analysis was restricted to only those parameters not influenced by sequencing or number of input cells. There was no difference in the number of productive T-cells identified in each cohort (p=0.18). However, the % maximal frequency clones were significantly higher in melanoma biopsies (p=0.0011, Figure 4A ). In addition, the lymphoma cohort had reduced clonality (p<0.0001) compared to the melanoma cohort ( Figure 4B ).
Research. immune checkpoint response within the TME. The TCR repertoire therefore appears to be related to the expression of checkpoint molecules within the TME. 
Discussion
This study shows the value of assessing the T-cell repertoire in the TME of malignant tumors. TCR sequencing correlated with gene expression and flow cytometry analysis. We showed that the TCR-repertoire within DLBCL nodes is abnormally narrow relative to non-diseased lymph nodes. Large clonal T-cell expansions were associated with inferior PFS and OS, and were most pronounced in patients with EBV + DLBCL. Finally, we showed that within diseased nodes there are a number of features indicative of an adaptive immune response. When combined, these findings implicate the TCR-repertoire as a key parameter of the TME and of survival, which has implications for the monitoring and design of future immune-based therapies.
In our study, there were significant differences in the TCR-repertoire between non-diseased and lymphomatous nodes. DLBCL nodes showed reduced levels of % total T-cells, but a more clonal and less diverse T-cell population compared to non-diseased nodes. These findings are consistent with the differences in TCRrepertoire seen between colon cancer biopsies and adjacent non-diseased mucosa. (24) In diseased nodes elevated checkpoint levels were associated with higher T-cell diversity (entropy). Together, these findings are in keeping with an adaptive immune response, in which malignant B-cells influence (i.e. 'adapt') the TME in an attempt to counter an effective anti-lymphoma T-cell response, which is in part influenced by the breadth of the TCR-repertoire. This adaptation to immune attack appears to be more marked in the presence of a diverse rather than a clonally restricted repertoire of tumor infiltrating T-cells. 
is unclear if T-cell responses are required to be antigen-specific or can, at least in part, mediate their effector activity through a non-specific bystander effect via local anti-tumor cytokine production.
Our findings provide interesting insights into a sub-group of DLBCL associated with high levels of EBV expression within the tumor. In melanoma, patients responsive to anti-PD1 therapy had significantly higher clonality measures compared to non-responders and a trend for a higher % maximal clone frequency. (7) It may be that patients with DLBCL who have a high % maximal frequency clone and inferior outcomes, would also be those to benefit most from the addition of anti-PD1 therapy.TCR sequencing might be helpful in identifying patients who would most benefit from these agents. We utilized an approach that focused on % frequency of clones rather than copy counts to allow comparison across samples with different T-cell inputs and thus differing sequence outputs. Also, the nature of the different T-cell subsets in which clones reside could not be determined, except that in general terms that higher CD8 RNA levels were associated with greater T-cell clonal expansions relative to CD4.
To our knowledge, this is the largest TCR sequencing analysis for any human cancer. The data demonstrates that the intra-tumoral T-cell repertoire in aggressive B-cell lymphoma is less diverse and more clonal than T-cell populations seen in non-diseased nodes. Tumors with large clonal T-cell expansions were associated with inferior outcomes that were independent of conventional prognosticators following conventional first-line therapy with R-CHOP. The TCR-repertoire is a key determinant of the TME. Collectively, these results provide important insights into a potential link between the TCRrepertoire and efficacy to R-CHOP in DLBCL, and should be factored in the rational design of novel immune-based therapies. The predictive utility of the Research.
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